NasdaqGS - Nasdaq Real Time Price USD

Alector, Inc. (ALEC)

1.0200

-0.0300

(-2.86%)

At close: May 7 at 4:00:01 PM EDT

Alector to Participate in Upcoming Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences: Bank of America Securities Health Care Conference (Las Vegas, Nevada) Tuesday, May 13, 2025, at 2:20 p.m. PT, corporate presentation H.C. Wainwright 3rd Annual BioConnect

GlobeNewswire yesterday

ALEC
-2.86%
Alector concludes enrolment in Phase II trial of Alzheimer’s treatment

GSK is carrying out the double-blind, placebo-controlled trial at several worldwide sites.

Clinical Trials Arena 16 days ago

ALEC
-2.86%
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease

--76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the completion of enrollment in PROGRESS-AD, a 76-week Phase 2 clinical trial evalu

GlobeNewswire 20 days ago

GLAXF

GSK

ALEC
-2.86%
Alector Provides Executive Leadership Update

--Giacomo Salvadore, M.D., appointed Chief Medical Officer-- --Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role-- SOUTH SAN FRANCISCO, Calif., March 28, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that Gary Romano, M.D., Ph.D., has made the decision to step down from his role as Chief Medical Officer. Dr. Rom

GlobeNewswire last month

ALEC
-2.86%
Alector Full Year 2024 Earnings: Beats Expectations

Alector ( NASDAQ:ALEC ) Full Year 2024 Results Key Financial Results Revenue: US$100.6m (up 3.6% from FY 2023). Net...

Simply Wall St. 2 months ago

ALEC
-2.86%
Q4 2024 Alector Inc Earnings Call

Q4 2024 Alector Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

ALEC
-2.86%
Alector Inc (ALEC) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ...

Alector Inc (ALEC) reports significant growth in collaboration revenue and advances in neurodegenerative disorder treatments, despite high R&D expenses.

GuruFocus.com 2 months ago

ALEC
-2.86%
Alector (ALEC) Reports Q4 Loss, Tops Revenue Estimates

Alector (ALEC) delivered earnings and revenue surprises of 96.88% and 220.64%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

ALEC
-2.86%
Alector: Q4 Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. AP) — Alector Inc. ALEC) on Wednesday reported a loss of $2.1 million in its fourth quarter.

Associated Press Finance 2 months ago

ALEC
-2.86%
Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK4527226 in participants with early Alzheimer’s disease by mid-2025 Applying Alector Brain Carrier to advance therapeutic candidates, including those targeting amyloid beta and replacing GCase $413.4 million in cash, cash equivalents and investments provide runway through 2026 Management to host conferen

GlobeNewswire 2 months ago

ALEC
-2.86%
Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call

Call Scheduled for Wednesday, February 26, 2025, at 4:30 p.m. ET/1:30 p.m. PTSOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Wednesday, February 26, 2025, at 4:30 p.m. ET to discuss results for the fourth quarter ended December 31, 2024, and provide a f

GlobeNewswire 2 months ago

ALEC
-2.86%
February 2025 US Penny Stocks With Promising Prospects

The U.S. stock market has been showing resilience, with the S&P 500 recently reaching an all-time high and major indices nearing record levels. In this climate, penny stocks—though often overlooked—can still offer intriguing opportunities for investors interested in smaller or newer companies. When backed by strong financials, these stocks may present a compelling mix of value and growth potential, making them worthy of consideration for those seeking promising prospects in the market.

Simply Wall St. 2 months ago

ALEC
-2.86%

BLND

ALXO
Discovering 3 US Penny Stocks With Market Caps Below $200M

As the U.S. stock market experiences a rise, driven by investor reactions to recent executive orders and economic policies, attention is drawn to various investment opportunities. Penny stocks, though often seen as relics of past market eras, continue to hold potential for investors seeking affordable growth prospects. These stocks typically represent smaller or newer companies that can offer significant upside when supported by strong financials and robust fundamentals.

Simply Wall St. 3 months ago

CLAR

OPRT

ALEC
-2.86%
Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company’s commitment to developing genetically-validated therapies for neurodegeneration Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Completion of enrollment in the PROGRESS-AD Phase 2 trial of AL101/GSK4527226 for early Alzheimer’s disease anticipated in mid-2025, with approximately 75% targe

GlobeNewswire 3 months ago

ALEC
-2.86%
ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study

Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.

Zacks 5 months ago

ALEC
-2.86%
Alector price target lowered to $7 from $35 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Alector (ALEC) to $7 from $35 and keeps a Buy rating on the shares. The company announced that the Phase 2 INVOKE-2 trial, which evaluated the TREM2 antibody, AL002 in Alzheimer’s disease patients, did not achieve its primary endpoint, the analyst tells investors in a research note. As a result, the firm removed AL002 from its valuation. Published first on TheFly – the ultimate source for real-time, market-moving breaking fin

TipRanks 5 months ago

ALEC
-2.86%
Alector stock drops after Alzheimer’s drug fails in Phase II trial

The company also stopped the long-term extension study for the AL002 and laid off 17% of its employees.

Clinical Trials Arena 5 months ago

ALEC
-2.86%
Alector turns to layoffs as Alzheimer’s drug fails

The brain drug developer is letting go of around 41 of its 238 employees, in a move the company says will help “align resources” with its strategic priorities.

BioPharma Dive 5 months ago

ALEC
-2.86%
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of neurodegenerative diseases, today announced results from the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). Treatment with AL002 resulted in sustained target engagement and pharmacodyna

GlobeNewswire 5 months ago

ALEC
-2.86%
Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $50 million. “Alector is in a strong cash position with more than $457 million in cash and investments. This credit facility further enhances our financial strength and provides the Company with increased strate

GlobeNewswire 5 months ago

ALEC
-2.86%

Performance Overview

Return	ALEC	S&P 500 (^GSPC)
YTD	-46.03%	-4.26%
1-Year	-80.75%	+8.55%
3-Year	-88.54%	+36.57%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Alector, Inc. (ALEC)

Alector to Participate in Upcoming Healthcare Conferences

Alector concludes enrolment in Phase II trial of Alzheimer’s treatment

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease

Alector Provides Executive Leadership Update

Alector Full Year 2024 Earnings: Beats Expectations

Q4 2024 Alector Inc Earnings Call

Alector Inc (ALEC) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ...

Alector (ALEC) Reports Q4 Loss, Tops Revenue Estimates

Alector: Q4 Earnings Snapshot

Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call

February 2025 US Penny Stocks With Promising Prospects

Discovering 3 US Penny Stocks With Market Caps Below $200M

Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study

Alector price target lowered to $7 from $35 at H.C. Wainwright

Alector stock drops after Alzheimer’s drug fails in Phase II trial

Alector turns to layoffs as Alzheimer’s drug fails

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

Performance Overview